Povidone-iodine (PVI) is an antiseptic drug that is used for wound healing or for repair of the damaged tissue. Studies on solid lipid nanoparticles (SLNs) indicate that this system could potentially be used as a delivery system with improved drug entrapment efficiency and controlled drug release for hydrophilic actives. This study focuses on developing a topical gel containing SLNs of PVI for wound healing. SLNs were prepared by using the solvent emulsification diffusion method. Lipids such as glycerol monostearate, palmitic acid, and stearic acid, and surfactants such as polysorbate 80, soyalecithin, and Pluronic F-68 were used for the preparation of SLN. These were screened out based on particle size and entrapment efficiency of SLN. Gel was prepared by using Carbopol 940 (1% w/w) and propylene glycol (10% w/w). Formulated SLNs were evaluated by various in vitro and in vivo techniques. Based on the results, the drug-to-lipid ratio (1:3) and 2% polysorbate 80 (surfactant) along with stirring rate (3,000 rpm) produced the desired particle size (285.4 nm) with good stability. 22.85% drug loading and 88.83% drug entrapment efficiency were found in the optimized formulation. In vitro drug release shows that it follows the Korsmeyer–Peppas model. The animal study shows that the period of epithelization produced by the test group was 17.14 ± 1.35 days, which was near to that of the standard group (16.25 ± 1.24 days). Clinical Trial Registration number: 1044/PO/Re/S/07/CPCSEA.

中文翻译：

---

用于伤口愈合的含聚维酮碘纳米颗粒的局部制剂的制剂开发

聚维酮碘 (PVI) 是一种防腐剂，用于伤口愈合或修复受损组织。对固体脂质纳米颗粒 (SLN) 的研究表明，该系统有可能用作递送系统，具有提高的药物包封率和亲水活性物质的受控药物释放。这项研究的重点是开发一种含有 PVI 前哨淋巴结的局部凝胶，用于伤口愈合。SLNs是通过使用溶剂乳化扩散法制备的。脂类如单硬脂酸甘油酯、棕榈酸和硬脂酸，以及表面活性剂如聚山梨酯 80、大豆卵磷脂和 Pluronic F-68 用于制备 SLN。这些是根据 SLN 的粒径和截留效率筛选出来的。通过使用 Carbopol 940 (1% w/w) 和丙二醇 (10% w/w) 制备凝胶。体外和体内技术。根据结果​​，药物与脂质比 (1:3) 和 2% 聚山梨醇酯 80（表面活性剂）以及搅拌速率 (3,000 rpm) 产生了具有良好稳定性的所需粒径 (285.4 nm)。在优化的配方中发现了 22.85% 的载药量和 88.83% 的药物包封率。体外药物释放表明它遵循 Korsmeyer-Peppas 模型。动物实验表明，试验组上皮形成周期为17.14±1.35天，与标准组（16.25±1.24天）相近。临床试验注册号：1044/PO/Re/S/07/CPCSEA。